✨
AI Summary
- OSE Immunotherapeutics discusses lusvertikimab's IL-7 data.
- CEO Poirier on commercialization and development strategy for IBD.
- Future outlook for Inflammatory Bowel Disease therapy.
Guests on This Episode
NP
Nicolas Poirier
1 podcast appearance